Motley Bio

Unlocking early disease biology with multiomics.

Motley Bio is a company in cancer based in Silicon Valley, California.

Profile

Motley Bio is a pioneering company in the fields of Artificial Intelligence, Deeptech, and Health, focused on unlocking early disease biology through multiomics technology. Their innovative multianalyte sequencing platform allows for the simultaneous profiling of DNA, RNA, and proteins in a single readout, enabling comprehensive analysis of a patient's genome, epigenome, transcriptome, and proteome for disease detection and profiling. Motley Bio's core intellectual property extends to both tissue and liquid biopsy profiling, offering a Multiomic Library Prep for simultaneous measurement of multiple omics data types and a Multiomic Analysis Toolkit for advanced data analysis and disease detection models. By providing a holistic view of a patient's molecular profile, Motley Bio is revolutionizing disease detection and therapeutic discovery in the healthcare industry.

Its activity falls under cancer; the profile below is assembled from public directory data.

Its base of operations is Silicon Valley, California.

The company is listed at the Creative Destruction Lab alumni company stage of development.

Website: motley.bio